MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

MYRIAD GENETICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026

$4.21+0.23 (+5.78%)

Close on Oct 19, 2026

Market cap: $399.11M
P/E (TTM): –
Dividend yield: –

MYRIAD GENETICS INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30	FY 2011 2011-06-30	FY 2010 2010-06-30	FY 2009 2009-06-30
Revenue	825	838	753	678	639	851	744	729	741	723	778	613	496	402	363	327
Cost of Revenue	248	252	236	202	–	–	–	145	133	133	96	64	51	46	44	43
Gross Profit	577	585	517	476	–	–	–	584	608	590	682	549	445	356	318	283
Research & Development	107	113	89	85	77	86	71	74	71	76	68	54	43	28	22	18
Selling, General & Admin	538	560	573	515	507	557	435	440	359	366	327	252	208	170	161	139
Selling & Marketing	281	284	289	267	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	257	276	284	248	–	–	–	–	–	–	–	–	–	–	–	–
Advertising Expenses	10	10	8.50	5.30	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	964	709	774	617	–	–	–	–	–	–	–	–	–	–	–	–
Total Costs & Expenses	–	–	1,011	819	870	844	622	685	587	589	504	385	316	244	228	200
Operating Income	-387	-124	-257	-141	-232	7.60	122	44	153	134	274	228	180	158	135	126
Interest Expense	11	2.80	2.90	3.20	11	12	3.20	6.00	0.30	0.20	–	–	–	–	–	–
Interest & Investment Income	1.80	1.70	2.50	2.60	3.00	3.20	1.80	1.20	0.90	0.40	5.40	5.50	4.63	2.23	5.66	12
Other Non-Operating Income	-7.90	0	-4.80	0	8.40	-7.60	-1.80	-7.80	2.60	0.70	3.40	5.30	4.22	1.87	–	–
Asset Impairment Charges	319	57	0	17	100	0	0	0	0	0	0	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	0.20	0.57	0.00	0.40	-1.99
Gain (Loss) on Sale of Assets	–	–	0	0	1.00	0	0.20	0.30	0.90	-0.50	-0.90	-0.01	-0.19	–	-0.50	-0.51
Legal Settlements	–	–	–	0	0	0	–	–	–	–	–	–	–	–	–	–
Pretax Income	-395	-124	-262	-141	-223	0	120	36	156	134	278	233	185	160	141	136
Income Tax Expense	-29	3.80	1.10	-29	-24	-4.40	-13	19	39	55	102	86	72	59	-11	0.19
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	112	101	152	136
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-52
Net Income incl. Noncontrolling Interests	–	–	–	-112	-200	4.40	133	17	117	80	–	–	–	–	–	–
Minority Interest in Earnings	–	–	–	0	-0.10	-0.20	-0.20	-0.20	–	–	–	–	–	–	–	–
Net Income	-366	-127	-263	-112	-200	4.60	133	17	117	80	176	147	112	101	152	85
EPS (Basic)(per share)	-3.95	-1.41	-3.18	-1.39	-2.69	0.06	1.92	0.25	1.67	1.12	2.33	1.82	1.33	1.12	1.58	0.91
EPS (Diluted)(per share)	-3.95	-1.41	-3.18	-1.39	-2.69	0.06	1.85	0.25	1.60	1.07	2.25	1.77	1.30	1.10	1.54	0.86
Shares Outstanding (Basic, Weighted)(shares)	93	91	83	81	74	74	69	68	70	71	76	81	85	90	96	93
Shares Outstanding (Diluted, Weighted)(shares)	93	91	83	81	74	76	72	69	73	75	78	83	86	92	99	99
EBITDA	-334	-62	-196	-88	-160	81	176	92	180	159	288	237	189	165	142	136

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 68.8%
Operating margin: -12.2%
Net margin: -14.0%
Return on equity, FY2025: -68.5%

Financial strength

Current ratio: 2.21
Debt to equity: 0.40
Debt to assets: 18.9%
Cash to current liabilities: 88.1%

Valuation

P/E ratio: –
Price to sales: 0.49
Price to book: 1.31
Dividend yield: –